




COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Docket No.: 239783US0



ATTORNEYS AT LAW

RE: Application Serial No.: 10/608,029

Applicants: Philippe DESPRES, et al.

Filing Date: June 30, 2003

For: ATTENUATED FLAVIVIRUS STRAINS
CONTAINING A MUTATED M-ECTODOMAIN
AND THEIR APPLICATIONS

Group Art Unit: 1648

Examiner: M.F.G. SALVOZA

SIR:

Attached hereto for filing are the following papers:

RESPONSE TO RESTRICTION REQUIREMENT

Our check in the amount of _____ is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Daniel J. Pereira, Ph.D.

Registration No. 45,518

Customer Number

22850

(703) 413-3000 (phone)

(703) 413-2220 (fax)

DOCKET NO: 239783US0

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

RE APPLICATION OF :
PHILIPPE DESPRES, ET AL. : EXAMINER: M. F. G. SALVOZA
SERIAL NO: 10/608,029 :
FILED: JUNE 30, 2003 : GROUP ART UNIT: 1648
FOR: ATTENUATED FLAVIVIRUS :
STRAINS CONTAINING A
MUTATED M-ECTODOMAIN AND
THEIR APPLICATIONS

RESPONSE TO RESTRICTION REQUIREMENT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Restriction Requirement mailed May 18, 2005, Applicants elect, with traverse, Group I: Claims 1-3, and 13, drawn to an isolated and purified peptide and a pharmaceutical composition.

REMARKS

The Examiner has required restriction of the above-identified application as follows:

- Group I: Claims 1-3 and 13 drawn to an isolated and purified peptide and a pharmaceutical composition;
- Group II: Claims 4-6 and 21, drawn to attenuated flavivirus strains, attenuated dengue strains, a chimeric flavivirus and a pharmaceutical composition;
- Group III: Claim 7, drawn to an isolated and purified polynucleotide;